SLC5A2 and type 2 diabetes mellitus: Furthermore, a comprehensive systematic review and network meta-analysis of RCTs provided direct evidence for the absolute benefits and harms of SGLT-2 inhibitors in reducing CV outcomes in patients with type 2 diabetes [67].